secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210324
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Q1 net loss $19.9M, cash $476.8M; RAP-219 Phase 3 in FOS on track for Q2 2026
--------------------------------------------------------------------------------

- Net loss $19.9M (vs $24.1M YoY); collaboration revenue $20.0M from Tenacia deal.
- Cash $476.8M at March 31, 2026; runway into 2H 2029.
- RAP-219 Phase 3 for focal onset seizures on track to begin Q2 2026; follow-up data showed 90% median seizure reduction weeks 9-12.
- Bipolar mania Phase 2 topline results now expected Q4 2026 (ahead of prior 1H 2027 guidance).
- R&D expense $32.7M (up from $19.6M); G&A $11.5M ($7.5M); Tenacia collaboration signed March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/0001193125-26-210324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer